Drug Discovery Unit

Scientists in the Wolfson Centre for Age-Related Diseases (CARD) are best known for their academic work on the molecular mechanisms that are involved in neurodegeneration, axonal regeneration and pain. The Neuroscience Drug Discovery Unit capitalises on our academic work. We have high throughput screening equipment, dedicated bioinformatics support with a molecular modeling and virtual screening capability and we run a number of in vitro and in vivo assays for target validation. The ultimate aim is the development of new medicines for neurodegenerative diseases and pain. The director of the unit is Dr Jonathan Corcoran who has been awarded two Wellcome Trust Seeding Drug Discovery grants (a total of over £7.5M) for the development of drugs for Alzheimer's disease and Spinal Cord Injury. The initiative will allow the College to pursue its commitment to translational research with pharmaceutical partners of excellence, supported by highly productive interactions between academics within the CARD and colleagues within King's Business